A Study of Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Plus Enfortumab Vedotin (EV) With and Without Pembrolizumab in Advanced Urothelial Carcinoma (MK-3475-04C/KEYMAKER-U04)

Trial Identifier: 3475-04C
Sponsor: MSD
Start Date: July 2024
Primary Completion Date: July 2028
Study Completion Date: July 2028

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

Language Description
Protocol Plain Language Summary-English
Protocol Plain Language Summary- English

Trial Locations

Country Location
Canada, ON Ottawa, ON, Canada, K1H 8L6
Canada, ON Toronto, ON, Canada, M5G 2M9
France, Rhone-Alpes Pierre-Benite, Rhone-Alpes, France, 69310
Israel, N/A Haifa, N/A, Israel, 3109601
Israel, N/A Petah Tikva, N/A, Israel, 4941492
Israel, N/A Ramat Gan, N/A, Israel, 5265601
Italy, Lombardia Milano, Lombardia, Italy, 20132
Korea, Republic of, Seoul Seoul, Korea, Republic of, 06351
Korea, Republic of, Seoul Seoul, Korea, Republic of, 05505
Korea, Republic of, Seoul Seoul, Korea, Republic of, 03722
Netherlands, Noord-Holland Amsterdam, Noord-Holland, Netherlands, 1066 CX
Spain, Barcelona Barcelona, Spain, 08035
Spain, Madrid Madrid, Spain, 28040
Taiwan, Tainan TAINAN, Tainan, Taiwan, 704
United Kingdom, London, City of London, London, City of, United Kingdom, EC1A 7BE
United States, CA San Francisco, CA, United States, 94158
United States, IN Indianapolis, IN, United States, 46202
United States, MA Boston, MA, United States, 02115
United States, MO St. Louis, MO, United States, 63108
United States, NY New York, NY, United States, 10029
United States, OH Cleveland, OH, United States, 44195
United States, UT Salt Lake City, UT, United States, 84112